News

Body monitoring specialist Xsensio raises CHF 4.2 million

With the closing of a CHF 4.2 million financing round, Xsensio will be able to advance its proprietary Lab-on-Skin sensing platform for continuous body monitoring through wearable devices.

Xsensio's Lab-on-Skin™ sensing chip
The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the EPFL.

Through its unique Lab-on-Skin sensing platform, Xsensio seeks to address the emerging field of wearable biosensing. By sensing biochemical information on the skin’s surface, the start-up’s technology provides unprecedented real-time information about our health and wellness in a simple and minimally invasive way.

In May 2021, Xsensio deployed its first Lab-on-Skin product in a pilot project at MotionLab. The aim was to monitor electrolytes in sweat to manage heat acclimation and dehydration of athletes, enabling better performance and reduced risk of injury in hot or humid environments such as the Olympic Games in Tokyo. Next year, the start-up based in Lausanne (canton of Vaud) plans to introduce the platform to elite and professional athletes.

The investment round is led by Privilège Ventures, a Swiss venture capital firm with offices in Lugano, Zurich and Boston, and included the EIC Fund and other international investors. The proceeds will expand product and platform development, run clinical validation, and accelerate market launch through commercial partnerships in Europe and in the US.

A paradigm shift in future healthcare delivery

“The technology holds the potential for a paradigm shift in the way we deliver healthcare in the future, with a stronger focus on prevention through the use of minimally-invasive health monitoring devices. We are grateful to our company board and our current and new investors for believing in our vision. We look forward to working with Privilège Ventures in this new phase of growth”, explains Esmeralda Megally, co-founder and CEO of Xsensio.

Jacqueline Ruedin Rüsch of Privilège Ventures, said : “We believe the opportunity for wearable biosensing is massive, and the team has the ambition and the talent to address this opportunity. I’m really excited to start this journey with Xsensio”.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Links

Share
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program